Although the pandemic nearly crushed their industries, these companies are finding ways to thrive.
The coronavirus had "a major impact" on slowing medical cost growth this year but the trend "is expected to be short-lived," a survey finds.
The company's Q1 results missed estimates but its performance "validates the strength, durability and flexibility of our business model.”
Mercer offers a comprehensive look at what health plan sponsors should be thinking about this contract season.
The long-entrenched system of drug-manufacturer rebates has not adapted to changes in health-plan designs and labor-market trends.
Annual hikes remain historically low for a second consecutive year, partly in response to corporate benefits strategies.
